Figure 2.
Current clinical management guidelines for Clostridium difficile infection (CDI). This diagram reviews the recommended treatment approaches for primary and recurrent CDI, depending on disease severity based on the 2018 IDSA/SHEA guidelines. Additionally, there is some evidence for fidaxomicin in place of rifaximin as a chaser for recurrent CDI and the EXTEND trial did show evidence for using extended-pulsed fidaxomicin for primary CDI; however, this is not currently reflected in the guidelines9,33,34,137.
* Primary CDI is defined as a new episode of symptoms with no previous positive C. difficile test result within 38 weeks and confirmation of CDI by diagnostic testing.